Phase II study of troxacitabine (BCH-4556) in patients with advanced non-small-cell lung cancer

Lung

Volumn 183, Issue 4, 2005, Pages 265-272

  Dent, S F ^a,c   Arnold, A ^a   Stewart, D J ^a   Gertler, S ^a   Ayoub, J ^a   Batist, G ^a   Goss, G ^a   Nevile, A ^a   Soulieres, D ^a   Jolivet, J ^b   Mclntosh, L ^a   Seymour, L ^a  

^a Queen's Cancer Research Institute   (Canada)

^b Shire Pharmaceutical Development Ltd   (Canada)

^c OTTAWA REGIONAL CANCER CENTRE   (Canada)

Author keywords

Non small cell lung cancer; Phase II; Troxacitabine

Indexed keywords

GLUCOSE; TROXACITABINE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTHRALGIA; ARTICLE; BIOCHEMISTRY; BLOOD TOXICITY; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; CONSTIPATION; COUGHING; DELUSION; DEPRESSION; DISEASE DURATION; DRUG ACTIVITY; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DYSPNEA; EMBOLISM; FATIGUE; FEMALE; GRANULOCYTOPENIA; HEMATOLOGY; HUMAN; HYPERGLYCEMIA; INFECTION; LUNG NON SMALL CELL CANCER; MALE; MALIGNANT NEOPLASTIC DISEASE; MOTOR NEUROPATHY; MULTICENTER STUDY; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; THROMBOSIS; VOMITING;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CYTOSINE; DIOXOLANES; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED;

EID: 26444620743     PISSN: 03412040     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00408-004-2539-7     Document Type: Article

References (19)

1. American Cancer Society (2000) Cancer Facts and Figures 2000. Atlanta, GA
2. American Society of Clinical Oncology(1997) American Society of Clinical Oncology, Clinical Practice Guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology. J Clin Oncol 15:2996-3018
3. Anonymous(1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group [see comments]. BMJ 311(7010):899-909
4. Attardo G, Kadhim S, Angers E, Bibeau L, Bowlin T (1997) Dose scheduling effects on the antitumor activity of BCH-4556 against human tumor xenografts in nude mice. In Proceedings of the American Association for Cancer Research Annual Meeting, San Diego, CA, Waverley Press, Volume 38, Abstract 670, p 38
5. Belanger K, Moore M, Baker SD, Dionne J, Maclean M, Jolivet J, et al.(2002) Phase I and pharmacokinetic study of novel L-nucleoside analog troxacitabine given as a 30-minute infusion every 21 days. J Clin Oncol 2010:2567-2574;erratum, J Clin Oncol 20(15):3361
6. Biochem Pharma Inc. (1999) Troxacitabine (BHC-4556). Investigator's Brochure. Laval, Quebec, Canada
7. Bouffard DY, Laliberte J, Momparler RL (1993) Kinetic studies on 2′,2′-difluorodeoxycytidine (Gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase. Biochem Pharmacol 459:1857-1861
8. Bowlin T, Genne P, Kadhim S, Gourdeau H, Attardo G (1997) A novel cytidine nucleoside analog, BCH-4556, with potent activity against human anthracycline-resistant leukemia. In Proceedings of the American Association for Cancer Research Annual Meeting, San Diego, CA, Waverley Press, Volume 38, Abstract 668, p 38
9. Canova A, Yee L, Baker S, Sarid R, Desforges C, Jolivet J, et al. (1999) A Phase I and Pharmacokinetic (PK) Study of β-L-Dioxalo-Cytidine (BCH-4556) Administered Weekly for Three Weeks Every 28 Days. In Proceedings of the Annual Meeting of the American Society of Clinical Oncologists, Atlanta, GA, ASCO, Alexandria, VA, Volume 18, Abstract 759
10. Cortes-Funes H (2002) New treatment approaches for lung cancer and impact on survival. [review] [18 refs]. Semin Oncol 29(3 Suppl 8):26-29
11. de Bono JS, Stephenson JJ, Baker SD, Hidalgo M, Patnaik A, Hammond LA, et al.(2002) Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies. J Clin Oncol 201:96-109
12. Gourdeau H, Bibeau L, Quellet F, Custeau D, Bernier L, Bowlin T (2001) Comparative study of a novel nucleoside analogue (Troxatyl, troxacitabine, BCH-4556) and AraC against leukemic human tumor xenografts expressing high or low cytidine deaminase activity. Cancer Chemother Pharmacol 473:236-240
13. Grove KL, Guo X, Liu SH, Gao Z, Chu CK, Cheng YC (1995) Anticancer activity of beta-L-dioxolane-cytidine, a novel nucleoside analogue with the unnatural L configuration. Cancer Res 5514:3008-3011
14. Kadhim SA, Bowlin TL, Waud WR, Angers EG, Bibeau L, DeMuys JM, Bednarski K, Cimpoia A, Attardo G (1997) Potent antitumor activity of a novel nucleoside analogue, BCH-4556 (beta-L-dioxolane-cytidine), in human renal cell carcinoma xenograft tumor models. Cancer Res 5721:4803-4810
15. Rabbani SA, Harakidas P, Bowlin T, Attardo G (1998) Effect of nucleoside analogue BCH-4556 on prostate cancer growth and metastases in vitro and in vivo. Cancer Res 58(15):3461-3465
16. Rivera MP (2001) Management of patients with advanced non-small-cell lung cancer [review] [37 refs]. Curr Opin Pulm Med 74:247-258
17. Sandler A, Ettinger DS (1999) Gemcitabine: single-agent and combination therapy in non-small cell lung cancer [see comments] [Review] [61 refs]. Oncologist 43:241-251
18. Smith IE, O'Brien ME, Talbot DC, Nicolson MC, Mansi JL, Hckish TF, et al. (2001) Duration of chemotherapy in advanced non-small-cell lung cancer: A randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol 19(5):1336-1343
19. Weitman S, Marty J, Jolivet J, Locas C, Von Hoff DD (2000) The new dioxolane, (-)-2′-deoxy-3′-oxacytidine (BCH-4556, troxacitabine), has activity against pancreatic human tumor xenografts. Clin Cancer Res 64:1574-1578